- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY3053102, Exenatide ER, Placebo, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Orange, California • Miami, Florida • Orlando, Florida + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 83
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Evaluate Ketogenic Stress
- Interventions
- Exenatide/Exenatide extended release, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Healthy Subjects
- Interventions
- Exenatide, Moxifloxacin, Placebo comparator
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Evansville, Indiana
- Conditions
- Type 2 Diabetes
- Interventions
- Bydureon, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 29
- States / cities
- Anaheim, California • Chino, California • Los Angeles, California + 26 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 51
- States / cities
- Peoria, Arizona • Artesia, California • Concord, California + 48 more
- Conditions
- Hyperinsulinemic Hypoglycemia
- Interventions
- Exenatide, Acarbose, Exenatide Placebo, Acarbose Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- exenatide, placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
- Conditions
- Multiple Sclerosis
- Interventions
- NLY01, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 10
- States / cities
- Peoria, Arizona • Jacksonville, Florida • Orlando, Florida + 7 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide (GSK716155) or exenatide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 158
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
- Conditions
- Cocaine Dependence
- Interventions
- cocaine hydrochloride, exenatide, placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Idiopathic Intracranial Hypertension
- Interventions
- Presendin, Placebo
- Drug
- Lead sponsor
- Invex Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
- Conditions
- Diabetes Mellitus
- Interventions
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
- Conditions
- Type 2 Diabetes
- Interventions
- placebo, exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 40
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
- Conditions
- Obesity
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Paul, Minnesota
- Conditions
- Obesity
- Interventions
- Exenatide, Placebo, Dietary counseling
- Drug · Behavioral
- Lead sponsor
- Jody Dushay
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, ITCA placebo
- Drug · Other
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more
- Conditions
- Type 2 Diabetes
- Interventions
- Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Orlando, Florida
- Conditions
- Obesity, Impaired Glucose Tolerance
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 25 Years to 60 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 14,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, ITCA placebo
- Drug · Other
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 4,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Hayward, California • Long Beach, California + 28 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 126
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
- Conditions
- Type2 Diabetes, Kidney Diseases
- Interventions
- Exenatide Extended Release for Inj Susp 2 MG, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Williamsville, New York